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ABSTRACT 
Background: Few studies have compared the sociodemographic characteristics and treatment 
outcomes of HIV/AIDS patients in rural and urban South Africa. 
Aim: This study compared the baseline socio-demographic characteristics and treatment 
outcomes (time to mortality, immunologic and virologic response) of HAART-naïve patients in 
urban and rural South Africa. 
Methodology: A secondary analysis of data obtained from the Themba Lethu Clinic, Helen 
Joseph Hospital, Johannesburg (urban site) and the ACTS clinic, Mpumalanga (rural site) from 
January 2005 to December 2008 was used to make comparison of baseline socio-demographic 
and clinical characteristics of patients in both cohorts. The survival experience and predictors of 
mortality was performed using Kaplan – Meier survival analysis and Cox proportional hazards 
models while effects on immunologic and virologic responses to HAART were modeled using 
logistic regression.  
Results: At initiation of HAART, the rural cohort had similar CD4 count and body mass index, but 
lower haemoglobin levels, compared to the urban cohort. The median follow up time for both 
cohorts was 566 days with the urban cohort having a mortality rate of 5.6/100 person-years 
compared to the 4.8/100 person-years of the rural cohort. CD4 count, BMI and WHO stage 
were predictors of mortality in both cohorts. Logistic regression models for virologic and 
immunologic response did not show any difference by site in the multivariate models.  
Conclusion: Though there are differences in the baseline sociodemographic and clinical 
characteristics of rural and urban patients starting HAART for the first time, achievement of 
immunologic and virologic response at 6 months of therapy were similar in both cohorts. 
Continued public health enlightenment campaigns and nutritional support programs should be 
undertaken to ensure patients present early and benefit from treatment. 
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DEFINITION OF TERMS 
1. EARLY MORTALITY: Death occurring within 6 months of commencing highly active 
retroviral therapy. 
2. Highly Active Antiretroviral Therapy: Antiretroviral drug combination consisting of two 
nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse 
transcriptase inhibitor or boosted protease inhibitor.  
3. Immunologic response: This is defined in this study as an increase of CD4 count, from 
initiation of HAART, of at least 50 cells/µl, within 6 months of therapy. 
4. Virologic response: A reduction in viral load to undetectable levels (<400 copies/ml) at 6 
months after HAART initiation.   
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
INTRODUCTION 
1.1 BACKGROUND 
The Human Immunodeficiency Virus (HIV) has created a formidable opposition to the 
achievement of health for all globally. Sub-Saharan Africa has been most affected – as at end of 
2007, about 22 million people were living with HIV. There is an estimated 1.9 million new 
infections annually and about 1.5 million deaths (1).  
South Africa has the largest number of people living with HIV in the world with an estimated 5.7 
million people living with HIV in the country at the end of 2007, including 3.2 million women. 
The adult (15 – 49 years) HIV prevalence is 18.1% and HIV accounted for 350,000 deaths in 
2007 only (1). Among antenatal care attendees the HIV prevalence is believed to be reducing 
(2). The national antenatal prevalence of 28.0% recorded in 2007 was a 1.1% reduction from 
the 2006 figure (2).  
The South African government decided to provide public access to HIV treatment in November 
2003 and 85,000 people were on treatment in the public sector as at September 2005 (3) . At 
the end of 2007, the World Health Organization (WHO) estimated 460,000 South Africans were 
on antiretroviral (ARV) treatment, 28% of those in need of treatment in South Africa(1).   
 In addition to the issue of health care personnel in rural areas, the distance of the health 
centres from the homes of the rural dwellers may be a deterrent to regular follow up visits. 
Information about HIV/AIDS may also be more limited in the rural areas thereby creating a 
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state of ignorance about the disease and encouraging its spread. Differences may also exist in 
the demographic, educational and economic characteristics of those in the rural and urban 
areas which may have an effect on the prevalence, rate of spread and outcome of treatment of 
HIV/AIDS patients. 
Antiretroviral therapy is now established in urban and rural South Africa but rural-urban 
differences in treatment outcomes have not been adequately studied. As access to 
antiretroviral therapy in the rural areas is being enhanced, it is important to determine if the 
rural patients are faring as well as those receiving treatment in the urban centres. 
If differences in treatment outcomes exist between these groups of patients, then it would be 
important to identify the characteristics responsible for this difference with the aim to modify 
these factors to ensure better treatment outcome.  
 
1.2 PROBLEM STATEMENT 
Sentinel surveillance has shown a steady increase in the HIV prevalence among pregnant 
women outside major urban areas in South Africa (1). It has been shown that death is a major 
reason for cohort exit in rural South African HIV patients on treatment (4). What we do not 
know is whether the mortality rates in these rural cohorts are the same as that obtained among 
the urban cohorts and what could account for such difference. There also has not been an 
extensive documentation of the differences that exist between rural and urban cohorts in 
South Africa, especially at the initiation of HAART.  
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1.3 JUSTIFICATION FOR THE STUDY 
Prevalence studies have been done in rural areas which have shown increasing prevalence of 
HIV/AIDS over the years (4, 5). There is little evidence indicating a difference in the treatment 
outcomes of HIV infected individuals in rural areas in South Africa compared to those in the 
urban areas. If the outcome of highly active antiretroviral therapy (HAART) is different in rural 
areas from that obtained from the urban areas (10), it would be important to identify the 
factors behind these differences and institute intervention programmes so as to ensure better 
HIV/AIDS treatment outcomes in South Africa.  
There is also the possibility that a difference in treatment outcome may arise from differences 
in baseline characteristics of the patients in the rural and urban areas. Such baseline 
characteristics may be the focus of an intervention program that will enhance treatment 
outcome.    
The findings of the study could help in planning more effective health service delivery to the 
HIV/AIDS patients in both urban and rural areas. Comparing the characteristics and treatment 
outcomes of the rural cohort with those in the urban centres would also potentially help inform 
policy makers of methods to optimize results in antiretroviral therapy and care for people with 
people with HIV/AIDS in all parts of South Africa. 
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1.4 LITERATURE REVIEW 
The HIV epidemic in South Africa was initially believed to be more pronounced in the urban 
areas in sub-Saharan Africa compared with rural areas but recently, studies in the Kwa-
ZuluNatal province of South Africa have demonstrated a rising prevalence of HIV/AIDS in rural 
communities. 
The changes in HIV prevalence in urban and rural South Africa 
The prevalence of HIV infection in women attending ante natal clinic in Hlabisa, Kwa-Zulu/Natal 
was noted to have significantly increased from 4.2% (95%CI, 3.0 - 5.7) in 1992 to 7.9% (95%CI, 
6.0 – 10.1) in 1993 and further to 14.0% (95%CI, 10.4 – 18.4) in 1995. At this time (1995), the 
seroprevalence in Durban antenatal clinics was estimated at 19% (95%CI, 16.5 to 21.7) (5). 
Though the prevalence remained higher in the urban area, the rate of rise in the rural area has 
been a reason for concern. By 1997, the antenatal HIV seroprevalence in rural Hlabisa had risen 
to 26% with the highest prevalence occurring in women aged 20-24 years (6). Frohlich et al 
noted that HIV prevalence among ANC attendees increased from 26% (2001) and, 34% (2002) 
to 41% in (2003) in rural KwaZulu Natal (7). This finding may not be generalized to other parts 
of South Africa. 
 Rural-urban migration has been implicated as one of the reasons for the increasing prevalence 
in rural areas. This was shown in a study in Carletonville, South Africa where the HIV prevalence 
among migrant women was significantly higher than non-migrant women; 46% vs. 34.7% (odds 
ratio 1.61, 95%CI of 1.11 – 2.3) (8). Also settlements that have a highly mobile population may 
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also be at increased risk of higher prevalence of HIV infection. This point is emphasized by a 
study in Tanzania which showed a two fold increase of HIV prevalence in a trading centre 
compared to an area 2 Km from the trading centre. It was shown that there was greater 
population mobility in those living in the trading centre than those inhabiting the villages only 2 
Km away from it (9).  
Others have suggested that differences in rural-urban HIV estimates may be because of the 
differences of the perceptions of health needs among these two groups. Work done in KwaZulu 
Natal suggests that knowledge about HIV/AIDS was relatively low and HIV and other sexually 
transmitted diseases were not perceived as a health priority among those in the rural areas 
(10).  
Sociodemographic, clinical and psychosocial differences between rural and urban HIV patients 
The difference between the rural and urban HIV populations is not limited to prevalence but 
may also include differences in sociodemographic characteristics. In a study of HIV patients in 
New England, it was shown that individuals with HIV in rural areas were older; the rural men 
were more likely to have sex with other men and had longer travelling time to their HIV care 
centre than individuals in urban areas (11). Though the rates of intravenous drug abuse and 
CD4 counts were the same at the onset of treatment, the mortality rate of individuals in the 
rural group was higher than that in the urban group (12). A similar study in the United States 
showed proportionately more males being infected in the urban areas than the rural area (13).  
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These differences may also be psychosocial in nature.  Heckman et al documented a 
significantly lower social and family well being in rural HIV patients in the USA (12). These rural 
patients also had more medical and psychological barriers preventing them from accessing 
treatment. They had greater fear of community stigma and less support from family and 
friends. The fear of discovery was also higher in patients in the rural area. There was no 
difference in the rate of denial in the two groups. Rural persons with HIV disease were noted to 
have longer distances to travel to access medical care, shortage of facilities and trained medical 
personnel in the hospitals they used, a lack of personal and public transportation and 
community residents’ stigma toward people living with HIV (13).  
Stigma has become a major problem in the provision of care for HIV/AIDS patients in Africa (14) 
and urban – rural differences exist in the magnitude of effect stigmatization has on the need to 
seek for care and remain adherent to HAART with rural dwellers experiencing less of the ill 
effects of stigma because of the communal lifestyle they have (15). 
There is little data on the geographical differences in the characteristics of HIV patients in South 
Africa. One of the few available studies compared the characteristics of patients on pre – ART 
care and on HAART for less than 6 months in 3 centres – one urban (the Helen Joseph Hospital 
in Gauteng); one semi-urban (Witkoppen health and welfare centre) and one rural centre (ACTS 
clinic at Mpumalanga) (16). 
This study showed a higher mean age at commencement of ARV in the rural area than the 
urban area. Also, the mean CD4 count at initiation of treatment was significantly lower in the 
rural area than urban centre. The educational status difference mirrored what is expected in 
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the rural-urban divide – the urban dwellers were generally better educated than the rural 
dwellers. There were significantly more women than men on ARV treatment in the rural cohort. 
Only 13% of those in the rural area had a formal sector job compared to 27% of those in the 
urban area. Those in the rural area were more unlikely to disclose their HIV status to their 
partners  (16). The emotional support given to these patients by their partners could encourage 
adherence to therapy and therefore better treatment outcomes. 
The relatively easier availability of health personnel and infrastructure in the urban areas 
indicate that there is better access to HAART in the urban than the rural centres (17). This could 
lead to worse treatment outcomes among the rural patients who are more likely to report late 
when complications of the disease have set in. 
Risk factors for mortality 
Several studies have identified predictors of poor outcome in varying patient cohorts. These 
factors range from sociodemographic characteristics to clinical factors present at or before 
initiation of HAART or occurring during the course of treatment. 
A South African study showed pulmonary tuberculosis and diarrhoeal disease to be common 
causes of mortality in HIV/AIDS patients living in rural South Africa (4). Late access to ARV 
program and subsequent advanced immunodeficiency (18), wasting syndrome, malignancy, 
acute bacterial infections and immune reconstitution syndrome (19) have been found to risk 
factors for early mortality among HIV patients in South Africa.  
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 Anaemia, thrombocytopenia and severe malnutrition have been shown to be independent 
predictors of mortality in rural cohorts of HAART naïve patients in rural Tanzania (20). HIV 
infected patients with low BMI on commencement of HAART, clinical stage IV disease and 
commencement of HAART with a stavudine-based therapy were associated with significantly 
lower increases of CD4 count after 6 months of therapy (21). The patients’ age at initiation of 
therapy, WHO clinical stage IV, a higher baseline HIV RNA, a body mass index less than or equal 
to 21 Kg/m2, low socioeconomic status and erythrocyte sedimentation rate greater than or 
equal to 60mm/hr have been found to be predictors of mortality (22, 23).  
Anaemia has been determined to be an independent predictor of mortality in HIV patients on 
HAART (24). Some are now arguing that this finding may not only be related to a reduced 
oxygen carrying capacity due to a low haemoglobin level but may also be associated with 
increased iron stores that occur when anaemia is present and genetic differences in the iron 
storage and iron carriage protein genes (25-27). Elevated transferrin, ferritin and a combined 
iron status index have been shown to be associated with increased risk of mortality (26). 
Anemia can also be a feature of opportunistic infections like Mycobacterial and parvovirus 
infections (20). Other mechanisms for anemia in HIV patients include impaired erythropoietin 
production in HIV associated nephropathy, micronutrient deficiencies, immunologic 
myelosuppression and chronic blood loss from intestinal helminthes (20). 
The nutritional status of patients also plays a significant role in predicting mortality in HIV 
patients. Body mass index (BMI) is used as a proxy for measuring nutritional status. Moderate 
to severe malnutrition (body mass index less than 17Kg/m2) has been found to be an 
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independent predictor of mortality (28) and there may be up to a six-fold increase in the risk of 
mortality among HIV patients with moderate to severe malnutrition compared to those with 
normal BMI (29). 
Immunologic response 
Immunologic response during HAART has been defined in various studies as an increase in CD4 
count of at least 50 cells/µL from baseline values after six months of HAART (30), attainment of 
CD4 cell count of greater than 200 X 106 /L in those who had counts less than 200 X 106 /L 
before commencement of HAART (31) and the achievement of at least 20% increase in the CD4 
count in those who had greater than 200 X 106 /L at commencement of HAART (31). 
Sustained immunologic response following use of HAART is regarded by most as a useful 
marker of good response to use of antiretrovirals. Studies have attempted to elucidate the 
factors that determine HIV patients that would achieve immunologic response. Baseline CD4 
count, baseline plasma HIV RNA level, use of protease inhibitors and WHO clinical stage at 
commencement of HAART have been noted as predictors of immunologic response (32, 33). 
Other immunological markers like the early CD8+ cell increase may be an indicator of sustained 
immunologic response in some HIV cohorts (34). 
An initial immunologic response may be followed by decline in CD4+ cell counts later in the 
course of treatment. The risk of immunologic failure following an initial immunologic response 
may be associated with the baseline CD4 count, ongoing viral replication (usually a 
manifestation of resistance to HAART), and intravenous drug use (35). A complex relationship 
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exists between viral replication and CD4 count changes and it is possible to have a discordant 
immunologic and virologic response (36-38). 
Virologic response 
The attainment of an undetectable viral load within 4 – 6 months of HAART (39, 40) defines 
virologic response to therapy. Virologic response at six months is usually the norm in the 
absence of resistance to HAART.  
The number of baseline reverse transcriptase inhibitors plus protease inhibitor – resistance 
mutations may predict virologic response in advanced HIV disease (41). Also, virologic rebound 
after an initial virologic response has been associated with low adherence to therapy, previous 
use of an antiretroviral drug before the commencement of a protease inhibitor based triple 
regimen, younger age at initiation of HAART and a higher baseline viral load level (42). 
Differences in the viral load at initiation of HAART and resistance patterns between the rural 
and urban patients may also be responsible for differences in treatment outcomes.       
Outcome differentia in rural and urban HIV patients  
Differences in urban and rural HIV patients in resource limited countries may be similar to 
differences documented between resource poor and developed countries. A large study 
comparing baseline characteristics and treatment outcome of HAART-naïve patients in resource 
poor and resource rich countries has shown that the low income countries have a lower median 
CD4 count at initiation of HAART, a greater proportion of females, with equal CD4 count 
11 
 
increases and equal HIV RNA reduction; mortality was nevertheless found to be significantly 
higher among those in the low income countries than the high income regions (43). 
The studies discussed above have shown that there usually exists a difference in the baseline 
sociodemographic characteristics of HIV patients in urban and rural centres which may impact 
on the treatment outcomes of the patients. It is therefore important to investigate these 
differences in the urban and rural cohort of patients and proceed to investigate if differences 
exist in their treatment outcomes. 
 
1.5 AIM OF THE STUDY:  
To compare the sociodemographic and clinical characteristics of patients commenced on 
HAART in the rural and urban areas of South Africa and assess differences in the treatment 
outcomes (mortality, immunologic and virologic response) in these areas. 
1.6 OBJECTIVES 
1. To compare the baseline sociodemographic and clinical characteristics of HIV patients 
initiated on HAART in urban and rural areas from January 2005 to December 2008. 
2. To compare the treatment outcomes (mortality, immunologic and virologic response) of 
HIV infected patients receiving HAART in rural and urban South Africa from January 
2005 to December 2008. 
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CHAPTER TWO: METHODOLOGY 
This study is a secondary analysis of data obtained during initiation of treatment and follow up 
of HIV patients receiving treatment at the Themba Lethu clinic, Helen Joseph Hospital, 
Johannesburg and the AIDS Care Training and Support (ACTS) Clinic at the Masoyi tribal area, 
Mpumalanga.  
2.1 Study Population 
The urban centre is located in Johannesburg, the large cosmopolitan city in Gauteng province of 
South Africa. The rural centre is at the foot of the Legogote mountains in the Masoyi tribal area 
of Mpumalanga province of South Africa.  
 
FIG 1: MAP SHOWING JOHANNESBURG AND THE MPUMALANGA PROVINCE WHERE THE RURAL SITE IS LOCATED. 
(COURTESY GOOGLE MAPS)  
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  The urban centre is at the Themba Lethu clinic, a comprehensive Care Management and 
treatment facility based in Helen Joseph Hospital in Johannesburg. It has a large patient base 
serving almost 20,000 HIV patients. Individuals who are HIV positive and meet the criteria for 
commencement of HAART are given two weeks of adherence counseling before treatment is 
commenced. At enrollment, important socio-demographic and clinical data is collected from 
the patient. The socio-demographic data includes age, gender, occupation, tobacco smoking 
and alcohol history. The clinical data includes history of tuberculosis, HIV related opportunistic 
infections and non-HIV related conditions. Others are patients’ vital signs and anthropometric 
measures (weight and height for BMI computation). If female, pregnancy status is ascertained. 
 Follow up medical visits are done four months after commencement of HAART and 6 monthly 
thereafter. In each follow up visit, clinical data is obtained from the patient to assess for 
response to therapy. A CD4 count and viral load is done and patients’ adherence to therapy is 
assessed. When indicated, patients deemed to be doing poorly are given more frequent follow 
up visits to enhance success of therapy.   
The study population from the rural area constitutes all patients seen at the AIDS Care Training 
and Support Clinic (ACTS) located at the Masoyi tribal area of Mpumalanga from January 2005 
to December 2008. The Masoyi tribal area has a population of 250,000 and the centre provides 
high quality HIV treatment and support for those infected and affected by the virus. About 
1,000 patients are seen monthly in the outpatient clinics and training of community care givers 
is also undertaken to care for AIDS patients at home (44). 
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Patients who visit the ACTS clinic usually would have voluntary counselling and testing (VCT). 
Individuals who test negative are counseled on adoption of a lifestyle that will ensure they stay 
negative. A case file is opened for individuals that test positive and have a positive confirmatory 
test. They then begin adherence and counseling clinic visits. At the second adherence visit, the 
counselor establishes if the patient has accepted his/her HIV status and is psychologically ready 
for HAART, if other indications for commencement of HAART are present. The adverse side 
effects and benefits of the use of antiretroviral therapy is discussed and the patient’s CD4 
count, viral load and other baseline tests including liver function and renal function tests 
performed. The importance of adherence to therapy is emphasized. 
Patient follow up is initially at 2 weeks after commencement of HAART, thereafter, if no 
complications occur, follow up is done every 3 months. At both sites, the patient can visit the 
clinic at any time in between follow up periods if any adverse health event occurs. 
The rural clinic also has strong support groups, where individuals commenced on HAART are 
encouraged to join one of the groups. The groups are formed along age group lines and have 
meeting time tables (see Appendix A). The caregivers in this centre believe these support 
groups are the key to maintaining a high level of patient adherence to therapy and curbing loss 
to follow up.   
Both sites use Therapy edge™ to capture patients’ data from initiation of therapy to all the 
follow up visits. Therapy edge™, developed by Therapyedge Inc USA and marketed by Advanced 
Biological Laboratories, is a web based decision support system for the treatment of HIV. It 
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graphically tracks and processes patient clinical information and helps the clinician in making 
decisions about patient care.  
2.2 STUDY DESIGN FOR SECONDARY DATA ANALYSIS 
This is a retrospective cohort study. Using data collected over a period of four years (January 
2005 – December 2008) in these HIV treatment sites, comparison of HIV treatment outcomes 
was performed for these two sites.  
STUDY OUTCOMES 
Three treatment outcomes were defined for this study, since any single outcome is not 
sufficient in itself to be used as a solitary measure of HIV treatment outcome. 
The outcomes measured include immunologic response, virologic response and time to 
mortality. 
 Immunologic response: This is defined in this study as an increase of CD4 count, from 
initiation of HAART, of at least 50 cells/µl, by 6 months of therapy (30). 
 Virologic response: A reduction in viral load to undetectable levels (<400 copies/ml) by 
6 months after HAART initiation (39).    
 Mortality – Confirmed death as documented on the database of the study sites in the 
period of study. 
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2.3 Study variables 
Other variables extracted from the databases included:  
 Socio-demographic data: Age at initiation of treatment (years); gender (male, female); 
educational level (years of formal education); history of tobacco and/or alcohol use, 
ethnicity (black or non-black), employment status (employed or unemployed). 
 Clinical data: CD4 count at commencement of therapy (number of cells/µL) and on 
follow up visits; viral load (copies/µL) on follow up visits; liver function tests; complete 
blood count; presence and type(s) of AIDS defining illnesses, nutritional status at 
commencement of therapy (measured using body mass index, BMI and serum albumin 
levels as proxy measures); presence of associated tuberculosis; initial HAART regimen 
the patient was commenced on; WHO stage of disease at the time of commencement of 
therapy. 
The laboratory tests were performed at initiation of therapy and at six month intervals at the 
urban centre if the patient is responding well to treatment. For patients with adverse effects of 
HAART or with complications of the disease, follow up is done at shorter intervals.  
 
Inclusion Criteria: All HIV positive adults aged 18 years and above commenced on ARV 
treatment in the study sites for the period January 2005 to December 2008. 
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Exclusion Criteria:   
 All patients on pre-ARV care. 
 All those who had received antiretroviral drugs prior to enrollment at the clinics.  
 All pregnant women at initiation of therapy because the increased blood volume during 
pregnancy tend to cause an underestimation of the CD4 count and viral load. After 
pregnancy, there is usually a sharp rise in the viral load. These fluctuations in the 
parameters used to assess outcome may affect my result, hence the exclusion of these 
subset of patients. Also, during pregnancy, the combination of antiretroviral drugs used 
changes.   
2.4 DATA ANALYSIS 
Data for all eligible patients were extracted from TherapyEdge-HIV™, a patient management 
and clinical decision support system developed by Advanced Biological Laboratories (ABL) and 
converted to .dta format for analysis using STATA. 
All analysis was done using STATA 10 statistical software (Stata Corp, Texas, USA). During data 
cleaning, duplicate entries were identified and removed. All individuals who were pregnant (93 
patients) or had used any combination of antiretroviral drugs (1038 patients) before 
presentation at these clinics were excluded. The frequency and proportion of missing values for 
each variable was examined. For each of the numeric variables, data entry errors were assessed 
for using the ‘summarize’ command in STATA and graphical display to locate outliers and 
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exclude those that were not biologically possible. All individuals with CD4 count at baseline 
greater than 550 cells/ µl were excluded from the study. These potentially corresponded to 
individuals who were not HAART-naïve. 
The datasets containing sociodemographic variables was merged with that containing the 
clinical variables for the two sites. Data from the rural site was appended to the urban site 
dataset to produce a single master dataset used for the analysis. 
A binary outcome was defined for mortality and time to death was determined from the 
initiation of HAART to the earliest of death, loss to follow up or end of the follow up period. For 
the purpose of modeling immune response, a new variable ‘immunres’ was created and coded 
“1” for those who were able to achieve at least 50 cells/ µl increase in their CD4 count at 6 
months of therapy and “0” for those who did not achieve this CD4 increase.  
To model virologic response, a new variable ‘vires’ was created and coded “1” for those that 
had a viral load level of < 400 copies/ml at 6 months of therapy and “0” for those who did not 
achieve this level of reduction in their viral load levels. 
 The baseline sociodemographic and clinical characteristics of the two cohorts were compared. 
For the numeric (continuous) variables – age, CD4 count at baseline, viral load at baseline, years 
of formal education, body mass index – the Wilcoxon rank sum test was used to test the 
equality of the median values of these variables in the two cohorts since these variables were 
not normally distributed. Normality was assessed both graphically (using box and whisker plots 
and histogram plots) and statistically (using the Shapiro-Wilk test). 
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The liver function tests, renal function tests and haemoglobin levels were categorized into 
normal and elevated (or deficient) categories and the Chi square was applied to test for 
association between the treatment site and these categorical variables. 
To compare the survival experience of both cohorts, Kaplan – Meier curves for both cohorts by 
gender were created and the equality of both curves tested using the log-rank test. Two Cox 
proportional hazard models were used to elucidate factors that predict mortality and to adjust 
for other factors that may have an effect on mortality. A direct comparison of the mortality 
rates in both cohorts was avoided because of the risk of mortality-ascertaining bias caused by 
the lack of updating of the rural mortality with the South African mortality database. Instead a 
comparison of the predictors of mortality was done. 
In building the multivariate model, variables are included singly into the model containing 
gender as the only predictor. All variables that change the point estimate of ‘gender’ on the 
outcome by at least 10% were retained in the model. This is continued till all the important 
variables are in the model. Interaction terms were then included into the model to assess for 
statistical interaction. An interaction term was deemed important in the model if the P – value 
of its Wald statistic was <0.05. The assumption of proportional hazards was then checked and if 
violated, time varying covariates were investigated and included into the model to obtain the 
final model. 
Logistic regression models were used to model both immunologic response and virologic 
response. Univariate analysis was first performed and crude odds ratios for the association of 
these variables with immunologic and virologic responses noted. Multivariate models were 
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built and interaction issues assessed for. The assumption of linearity in the logit scale was also 
assessed and the Hosmer – Lemeshow goodness of fit test was used for model diagnostics. Also 
the sensitivity of the model was obtained and a receiver operator characteristic (ROC) curve for 
each of the logistic regression models was plotted so as to calculate the area under the curve 
and assess the functionality of the model. 
 
2.5 ETHICAL CONSIDERATIONS 
Ethical clearance was obtained from the University of Witwatersrand Committee for Research 
on Human Subjects (medical) for permission to carry out this study (Protocol number M090943, 
approved 02/10/2009), Appendix B. The Clinical HIV Research Unit of the Themba Lethu Clinic 
at the Helen Joseph Hospital also granted approval for the use of the primary datasets 
(Appendix C1 and C2). 
The dataset was anonymized before I had access to it and there was no contact between the 
patients and myself. 
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CHAPTER 3: RESULTS 
3.1 DESCRIPTIVE ANALYSIS 
A total of 10,451 observations were included in the analysis. 1992 (19.1%) were from the rural 
site while 8459 (80.9%) received treatment in the urban centre. Table 1 gives a description and 
comparison of the baseline socio-demographic characteristics of the cohorts.  
TABLE 1: DESCRIPTION AND COMPARISON OF BASELINE SOCIO-DEMOGRAPIC CHARACTERISTICS* 
SOCIODEMOGRAPHIC FACTORS URBAN (N=8459) RURAL (N=1992) RELATIVE RISK (95% CI) 
Age at initiation of HAART [year; 
median (IQR)] N 37.1 (31 – 42.2) 8459 38.3 (31.1 – 43.6) 1992 
µ 
Female gender n/N (%) 5351/8459 (63.3)  1252/1992 (62.9) 1 (0.98 – 1.02) 
Black ethnicity n/N (%) 8088/8459 (95.6) 1728/1992 (86.8) 2.47 (2.27 – 2.68) 
Employed n/N (%) 3793/8307 (45.7) 342/1778 (19.2) 1.21 (1.19 – 1.23) 
Smoking history n/N (%) 
   Current smoker 
   Prior history 
   Never smoked 
 
886/8067 (11.0) 
459/8067 (5.7) 
6722/8067 (83.3) 
 
118/1769 (6.7) 
55/1769 (3.1) 
1596/1769 (90.2) 
 
1.09 (1.06 – 1.12) 
1.10 (1.07 – 1.14) 
1 
Alcohol Use n/N (%) 
   current user 
   Prior history 
   Never used 
 
944/8086 (11.7) 
744/8086 (9.2) 
6398/8086 (79.1) 
 
128/1766 (7.3) 
55/1766 (3.1) 
1596/1766 (90.2)  
 
1.09 (1.07 – 1.12) 
1.08 (1.05 – 1.11) 
1 
Years of formal education n/N (%) 
            ≥ 6 years  
 
7030/8111 (86.7) 
 
515/960 (53.7) 
 
 
1.32 (1.27 – 1.36) 
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*the categorical variables were compared using the Chi-square while the Wilcoxon rank sum test was used to compare the medians of the numeric 
variables.   
µ = P-values <0.05.  
 
FIGURE 2: BOX AND WHISKER PLOTS COMPARING THE AGE DISTRIBUTION OF TREATMENT COHORTS 
The patients from the rural site have a higher proportion of non-black patients than those in 
the urban site. The sex distribution was similar across the sites. A greater proportion of the 
urban patients were employed, smoking tobacco actively and taking alcohol regularly. There 
was 32% increased likelihood for a patient in the urban cohort to have at least six years of 
formal education (95% CI, 1.27 – 1.36).  Figures 2 and 3 compare graphically, the age and 
gender distribution of both cohorts. 
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FIGURE 3: BAR CHART SHOWING THE SEX DISTRIBUTION BY TREATMENT SITE 
Table 2 compares the baseline clinical characteristics of the patients in both sites.  
The urban cohort had higher median CD4 counts but a lower proportion (83.0% vs. 88.8%) was 
commenced on the stavudine – lamivudine – efavirenz combination as first line therapy instead 
of the stavudine – lamivudine – nevirapine comination. The urban cohort also had a higher 
proportion of patients with early stages of HIV disease and lesser proportion with anaemia. 
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TABLE 2: COMPARISON OF BASELINE CLINICAL CHARACTERISTICS 
CLINICAL CHARACTERISTIC URBAN (N = 8451) RURAL (N = 1992) RELATIVE RISK (95% CI) 
Baseline CD4 count [cells/UL; 
median (IQR)]N 
89 (32 – 158) 8451  78 (25 – 159) 1992 µ  
Initial regimen n/N (%) 
    d4T/3TC/EFV* 
    d4T/3TC/NVP** 
    Others 
  
6897/8299 (83.0) 
553/8299 (6.6) 
977/8299 (10.4) 
  
1703 (88.8) 
61 (3.1) 
220 (9.1) 
 
1 
1.12 (1.09 – 1.15) 
1.02 (0.99 – 1.05) 
Baseline BMI [kg/m2; median 
(IQR)] N 
21.5 (19 – 24.7) 7304 20.3 (18 – 23.7) 1237 µ  
TB at initiation of HAART  1285 (15.2) 8451  282 (14.2) 1992 1.02 (0.99 – 1.04) 
WHO stage n/N (%) 
    I 
    II 
    III 
    IV 
 
4451/8451 (52.67) 
147/8451 (1.74) 
3081/8451 (36.42) 
780/8451 (9.22) 
 
979/1992 (49.15) 
26/1992 (1.31) 
761/1992 (38.20) 
226/1992 (11.35) 
 
1 
1.07 (0.97 – 1.11) 
0.98 (0.96 – 0.99) 
0.95 (0.91 – 0.98) 
Anaemia  n/N (%)  2026/7766 (26.1)  693/1574 (44) <0.001 
*stavudine-lamivudine-efavirenz combination. **stavudine-lamivudine-nevirapine combination 
µ = P-values <0.05. These were statistically significant because of the large sample size but with no clinically significant difference. 
 
Anaemia was defined as haemoglobin of less than 10g/dl.  The proportion of TB cases at 
initiation of HAART for both cohorts was similar. 
3.2 COMPARISON OF THE SURVIVAL EXPERIENCE OF BOTH COHORTS 
1009 patients died in both cohorts during the period of study, putting the average mortality risk 
during the period of follow up at 9.65%. 141 (7.1%) died among the rural cohort while 868 
(10.3%) died among the urban patients throughout the follow up period. 592 people, overall, died 
within 6 months of commencing HAART. This constitutes 58.7% of the total number of people that died 
during the 4 years of the study period. This means more than half of the deaths experienced after 
HAART commencement occur within the first 6 months of commencing HAART. 
25 
 
The median follow up time for the study was 566 days. The mortality rate was 4.8 per 100 
person-years for the rural cohort and 5.6 per 100 person-years for the urban cohort. An 
investigation into the incidence rates in the two cohorts for specific periods during follow up 
was done and this is represented in table 3 below. 
TABLE 3: MORTALITY RATES FOR SPECIFIC PERIODS FOR BOTH COHORTS  
PERIOD URBAN RURAL 
NO. OF 
DEATHS 
MORTALITY RATE PER 100 PERSON-
YEARS (95% CONFIDENCE 
INTERVAL) 
NO. OF 
DEATHS 
MORTALITY RATE PER 100 
PERSON-YEARS (95% CONFIDENCE 
INTERVAL) 
0 – 6 
MONTHS 
496 12.6 (11.5 – 13.8) 95 10.3 (8.5 – 12.7) 
6 – 12 
MONTHS 
174 5.6 (4.8 – 6.5) 27 4.0 (2.7 – 5.8) 
12 – 24 
MONTHS 
125 2.8 (2.3 – 3.3) 14 1.7 (1.0 – 2.9) 
24 
MONTHS 
+ 
69 1.7 (1.4 – 2.2) 5 1.0 (0.4 – 2.5) 
 
In all the specific time periods, the mortality rate appeared to be higher in the urban cohort 
than the rural cohort. It is also observed that the highest rates of mortality were recorded in 
the first six months after commencing HAART and the mortality rates were reducing 
progressively with time in both cohorts.  
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FIGURE 4: KAPLAN-MEIER GRAPH SHOWING THE SURVIVAL EXPERIENCE OF BOTH GENDERS IN 
THE URBAN COHORT.  
Figure 4 shows the survival experience of both genders in the rural cohort. The females appear 
to have a better survival experience than the males in the urban cohort during the period of 
study unlike the rural cohort where both genders have similar survival experience (see figure 5). 
Two Cox models were built to investigate the predictors of mortality in both treatment cohorts. 
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FIGURE 5: KAPLAN – MEIER CURVES SHOWING THE SURVIVAL EXPERIENCE OF BOTH GENDERS 
IN THE RURAL COHORT. 
3.3 MODELLING THE SURVIVAL EXPERIENCE IN BOTH COHORTS 
Two Cox proportional hazard models were used to investigate the factors that predict mortality 
in the rural and urban cohorts. The age at initiation of therapy, male gender, body mass index, 
CD4 count, haemoglobin and WHO disease stage at the beginning of treatment, predicted 
mortality in the urban cohort. BMI was categorized into underweight (<18 kg/m2), normal (18 – 
24.9 kg/m2), overweight (25 – 29.9 kg/m2) and obese (≥ 30 kg/m2). 
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TABLE 4: UNIVARIATE AND MULTIVARIATE COX REGRESSION MODELS FOR 
THE URBAN COHORT 
VARIABLE UNIVARIATE 
HAZARD RATIO (95% CI) P-value 
MULTIVARIATE** 
HAZARD RATIO (95% CI) P-value 
Age (5 years)  1.09 (1.05 – 1.13) <0.001 1.10 (1.06-1.15) <0.001 
Male gender 1.45 (1.27 – 1.66) <0.001 1.34 (1.16-1.56) 0.006 
BMI (Kg/m2) 
     Underweight 
     Normal 
     Overweight 
     Obese 
 
1 
0.44 (0.37 – 0.72) <0.001 
0.29 (0.22 – 0.38) <0.001 
0.70 (0.58 – 0.84) <0.001 
 
1 
0.60 (0.50 – 0.72) <0.001 
0.50 (0.37 – 0.67) <0.001 
1.00 (0.82 – 1.23) 0.97 
CD4 count (per 10 cells/UL) 0.94 (0.91-0.94) <0.001 0.95 (0.94-0.96) <0.001 
Haemoglobin (g/dl) 0.83 (0.81 – 0.86) <0.001 0.87 (0.84 – 0.90) <0.001 
WHO Stage 
     I 
     II 
     III 
     IV 
 
1 
1.48 (0.91 – 2.42) 0.11 
1.68 (1.45 – 1.95) <0.001 
2.43 (1.98 – 2.97) <0.001 
 
1 
1.33 (0.76 – 2.32) 0.31 
1.12 (0.95 – 1.31) 0.17 
1.37 (1.10 – 1.71) 0.01 
**Note: 7774 patients were included in the final multivariate Cox model. 
Univariate analysis for the urban cohort showed males had a hazard ratio of 1.45 (95%CI of 1.27 
– 1.66); for every 5 year increase in age, the risk of mortality increased by 9%. Other covariates 
that significantly predict mortality at the univariate level of the analysis include BMI (there was 
lower mortality for individuals who were normal or overweight compared to those who were 
underweight at initiation of therapy); the higher the CD4 levels at baseline, the lower the risk of 
mortality; WHO Stage 3 and 4 HIV disease; serum creatinine at baseline; serum alanine and 
aspartate transaminases levels at baseline, serum albumin level at initiation of HAART and 
haemoglobin levels.  
The final multivariate model for the urban cohort (Table 4) showed a 37% increased rate of 
mortality for patients in WHO stage 4 disease at the onset of treatment compared to those in 
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Stage 1. Anaemia was also a predictor of mortality with a hazard ratio of 0.87 (95%CI 0.84-0.90) 
for every g/dl increase in hemoglobin if other factors are kept constant. The other protective 
factors against mortality included BMI. There was a 40% reduction in the risk of mortality for 
the normal weight individuals compared to the underweight patients. Those overweight at 
initiation of therapy also had a lower risk of mortality compared to the underweight. The obese 
individuals did not show any difference in their risk of mortality compared to the underweight. 
For every 10 cells/µL increase at baseline, the risk of mortality reduced by 5%. Males in the 
urban cohort were more likely to die and for every 5 year increase in age, the risk of mortality 
in the urban cohort increased by 10%. 
TABLE 5: UNIVARIATE AND MULTIVARIATE COX REGRESSION MODELS FOR 
THE RURAL COHORT 
VARIABLE UNIVARIATE 
HAZARD RATIO (95% CI) P-value 
MULTIVARIATE** 
HAZARD RATIO (95% CI) P-value 
BMI (Kg/m2) 
     Underweight 
     Normal 
     Overweight 
     Obese 
 
1 
0.44 (0.37 – 0.72) <0.001 
0.29 (0.22 – 0.38) <0.001 
0.70 (0.58 – 0.84) <0.001 
 
1 
0.64 (0.41 – 1.02) 0.06 
0.16 (0.03 – 0.66) 0.01 
0.79 (0.51 – 1.20) 0.26 
CD4 count (per 10 cells/UL) 0.95 (0.93-0.97) <0.001 0.94 (0.93-0.99) <0.001 
No history of Pulmonary TB 0.79 (0.47 – 1.33) 0.39 0.33 (0.15 – 0.72) 0.006 
WHO Stage 
     I 
     II 
     III 
     IV 
 
1 
2.72 (0.84 – 8.76) 0.11 
2.21 (1.50 – 3.24) <0.001 
3.27 (2.03 – 5.27) <0.001 
 
1 
2.13 (0.29 – 15.82) 0.46 
2.44 (1.44 – 4.15) 0.001 
2.14 (1.10 – 4.17) 0.026 
**Note: 1992 patients were included in the final multivariate Cox model. 
BMI, CD4 count at baseline and WHO stages at commencement of HAART were also important 
predictors of mortality in the rural cohort as they were for the urban cohort (Table 5). After 
adjusting for CD4 count, history of pulmonary TB and WHO stages, there is 84% reduction in the 
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risk of mortality in the overweight compared to the underweight. Unlike the urban cohort, 
those with normal weight did not show any difference in their risk of mortality compared to the 
underweight individuals at initiation of HAART. The obese, like in the urban cohort, did not have 
a different mortality risk compared to the underweight. The higher the CD4 count at initiation 
of HAART, the lesser the risk of mortality. Those in the rural cohort without a history of co-
infection with tuberculosis have a 67% reduced mortality rate after adjusting for BMI, CD4 
count at initiation of HAART and WHO stage of the disease. Individuals in WHO stage 3 and 4 at 
commencement of HAART are also more likely to die compared to those in stage 1 after 
adjusting for BMI, CD4 count and co-infection with tuberculosis. 
3.4 IMMUNOLOGIC RESPONSE 
10451 patients met the inclusion criteria for analysis. Of these, 2182 (20.9%) were lost to follow 
up during the first 6 months after commencement of HAART. 592 (5.7%) died within 6 months 
of therapy.  77% of the patients who were still alive and not lost to follow up at 6 months had 
achieved immunologic response. This constitutes 80.5% of the patients in the rural site and 
76.3% of the urban patients. Figure 6 shows the patient flow for both cohorts combined and 
Figure 7 shows graphically the increase in CD4 count in both cohorts over 6 months of therapy. 
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FIGURE 6: PATIENT FLOW CHART AT 6 MONTHS OF THERAPY 
The mean change in CD4 count was 149 cells/ µL and 122 cells/µL for the rural and urban site 
respectively. The difference in CD4 count for both cohorts was 27 cells/ µL (95% CI, 15 – 40 
cells/ µL). 
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FIGURE 7: BOX PLOTS SHOWING DISTRIBUTION OF CD4 COUNT AT BASELINE AND 6 MONTHS AT BOTH SITES 
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Both univariate and multivariate logistic regression models were used to compare the 
treatment site effect on the achievement of immunologic response and to assess other factors 
that predict immunologic response. This is summarized in table 6 below. 
TABLE 6: UNIVARIATE AND MULTIVARIATE LOGISTIC REGRESSION MODELS FOR 
IMMUNOLOGIC RESPONSE 
VARIABLE UNIVARIATE 
ODDS RATIO (95% CI, P-value) 
MULTIVARIATE** 
ODDS RATIO (95% CI, P-value) 
Sites 
     Rural 
     Urban 
 
1 
 0.78 (0.67-0.91, 0.001) 
 
1 
0.94 (0.73 - 1.22, 0.66) 
Age (5 years interval) 0.91 (0.88-0.94, <0.001) 0.92 (0.89-0.96, <0.001) 
Gender* 
     Female 
     Male 
 
1 
 0.72 (0.65-0.81, <0.001) 
 
1 
1.28 (0.83-1.99, 0.27) 
 
CD4 count at baseline (10 
cells/UL) 
0.68 (0.64-0.72, <0.001) 0.65 (0.60-0.70, <0.001) 
BMI at baseline (kg/m2) 1.00 (0.95-1.07, 0.86) 1.11 (1.03-1.19, 0.005) 
Haemoglobin at baseline 
(g/dl) 
0.92 (0.89-0.94, <0.001) 0.96 (0.93-0.99, 0.01) 
*statistical interaction exists between patient’s gender and treatment site. 
**5694 observations were included in the model.                                                                                                                                                                                                                                                                                                                                                                                       
 
The final multivariate logistic regression model suggests that both urban and rural cohorts have 
equal chances of achieving immunologic response. 
For every five year increase in age at initiation of treatment, patients are 8% less likely to 
achieve immune response. The higher the CD4 count at initiation of therapy, the less likely (35% 
less for every 10 cells/UL increase) that an individual will achieve a CD4 appreciation of at least 
50 cells/µL after 6 months of therapy. 
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There is an 11% increase in the odds of achieving immune response for every Kg/m2 of BMI 
increase at baseline and a 4% decrease in the odds of achieving immune response for every g/dl 
increase in haemoglobin level all other factors being held constant. 
The final multivariate model did not violate the assumption of linearity in the logit scale. 
Goodness of fit of the model was assessed using the Hosmer – Lemeshow goodness of fit test. A 
P – value of 0.68 for the Hosmer –Lemeshow test suggests the model has a good fit. The 
sensitivity of this multivariate model in predicting immunologic response as defined in this 
study is 99.6% with a positive predictive value of 77.2% and a negative predictive value of 
51.3%. 
A receiver operator characteristic (ROC) curve was plotted to assess the area under the curve 
for this model. The area under the curve for the model is 62.6%. Please see appendix D for the 
ROC curve tracing. 
 
 
 3.5 VIROLOGIC RESPONSE 
Of the 10451 patients available for analysis after application of the inclusion and exclusion 
criteria, 592 (5.7%) died within 6 months of commencing HAART, 2182 (20.9%) had been lost to 
follow up and 972 (9.3%) had no data recorded for their viral load at 6 months. 6705 (64.2%) 
were available for modeling of virologic response. 6123 (91.3%) of the patients had achieved 
virologic response by 6 months, comprising 914 (90.3%) of the rural patients and 5209 (91.5%) 
of the urban patients. This patient flow is shown in figure 8. 
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FIGURE 8: PATIENT FLOW FOR INDIVIDUALS USED IN VIROLOGIC RESPONSE MODELLING 
A logistic regression model was fitted to compare the effects of the two treatment sites on the 
achievement of virologic response and elucidate factors that predict virologic response. Table 7 
gives a summary of the univariate and multivariate models. 
Both the univariate model and the final multivariate model show that there is no difference in 
the proportion of individuals in the cohort attaining virologic response. Age at initiation of 
therapy is important in predicting virologic response like its effect on predicting immunologic 
response and time to mortality. The odds ratio of achieving virologic response for every five 
year increase in age is 1.08 (95% confidence interval of 1.03 – 1.15). Patients who were 
unemployed at the time of initiation of HAART were 33% less likely to achieve immune 
response compared to those employed, all other factors remaining unchanged.  
For every 10 cells/µL increase in CD4 count at initiation of HAART, there is a 16% increase in the 
odds of achieving virologic response, all other factors held constant. 
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No interaction issue was significant in the model. Model diagnostics were then performed. 
TABLE 7: UNIVARIATE AND MULTIVARIATE LOGISTIC REGRESSION MODELS FOR VIROLOGIC 
RESPONSE 
VARIABLE UNIVARIATE 
ODDS RATIO (95% CI, P-value) 
**MULTIVARIATE 
ODDS RATIO (95% CI, P-value) 
Sites 
    Rural 
    Urban 
 
1 
          1.15 (0.92-1.45, 0.22) 
 
1 
   1.08 (0.85 – 1.38, 0.54) 
Age* 1.02 (1.01-1.03, 0.001) 1.08 (1.03-1.15, 0.02) 
Employment status 
     employed 
     Unemployed 
CD4 count (per 10 cells/µL) 
     
 
1 
0.69 (0.57-0.82, <0.001) 
1.19 (1.06 – 1.32, 0.002) 
 
1 
                0.67 (0.54-0.82, <0.001) 
1.16 (1.04 – 1.30, 0.007) 
*In Units of 5 years. 
**6551 observations included in the model. 
 
The assumption of linearity on the logit scale was assessed for and ensured that it was not 
violated. The fit of the model was adjudged to be good by the Hosmer – Lemeshow goodness of 
fit test. 
 The model has 100% sensitivity and an area under the ROC curve of 58.8%. The ROC curve for 
the model is shown in appendix E. 
Three HIV treatment outcomes – time to mortality, immunologic response and virologic 
response – have been used to compare the success of HIV treatment in an urban and a rural 
HIV treatment site in South Africa. 
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The four models used to predict these outcomes suggest that both urban and rural cohorts 
share similar predictors of mortality and there is no difference in the proportions achieving 
virologic and immunologic response at six months of therapy. 
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CHAPTER 4: DISCUSSION, LIMITATIONS OF THE STUDY AND CONCLUSION 
4.1 DISCUSSION 
This comparison of HIV treatment outcomes in urban and rural South Africa was done on 
HAART-naïve patients to eliminate the possibility of previous HAART therapy being a 
confounder in the study. Also, the exclusion of pregnant women from the study helped avoid 
the confusion that may arise from fluctuations in CD4 count that occur during pregnancy and in 
the immediate post-partum period.   
Patients from the rural site started treatment with a lower CD4 count and a more advanced HIV 
disease as evidenced by a greater proportion of patients with WHO stage 3 and 4 disease. This 
finding is supported by a similar study in South Africa comparing the clinical and 
sociodemographic characteristics of patients commencing HAART in an urban and a rural centre 
(16). This study also corroborated the finding of better formal education and formal 
employment in the urban centre compared to the rural centre. The assumption is that the rural 
patients, having fewer years of formal education and living in rural settings, may not be able to 
access information on HIV/AIDS, therefore they tend to present late as evidenced by the lower 
median CD4 count and a greater proportion of more advanced HIV disease in the rural cohort. 
The rural cohort also had a significantly lower proportion of patients in formal employment, 
therefore, lower earning power. This comes as a disadvantage to early presentation to ARV 
centres for care and compliance to clinic visits after commencement of HAART. Unfortunately, 
the rural centre charges a token fee for every clinic visit. This token fee, though small, may have 
a profound effect on default of patients due to financial constraints. The unemployed were less 
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likely to achieve virologic response at 6 months of HAART. This point emphasizes the need to 
provide a source of livelihood for people living with HIV/AIDS. 
Both sites saw more females commencing HAART than males but there was no difference in the 
gender proportions by site. Though the CD4 count in the rural cohort was lower at initiation of 
therapy than the urban cohort, both cohorts had similar HIV RNA load at initiation of HAART. 
This finding is important to note as it may have an influence on the likelihood of the patients to 
achieve immunologic and virologic response. It is also possible to achieve virologic response 
without having a concomitant immunologic response and vice-versa. Some studies have 
reported the finding of discordance between the viral load and the CD4 count response 
following HAART (37).   
Another baseline clinical characteristic that merits discussion is the nutritional state of the 
patient. In this study, the BMI and serum albumin were used as proxies for measuring 
nutritional status as these were the best available parameters collected in this retrospective 
analysis. The merits and demerits of BMI as an indicator of nutritional status has been noted 
(45). Many hold the view that the BMI is a complicated tool for use in public health studies and 
should be reserved for clinical studies (34). Another disadvantage of using BMI may be the issue 
of standardization of the scales used for weight measurement in both centres. Despite these 
few demerits, the BMI is still one of the best available tools in measuring nutritional status (34). 
This study showed a higher BMI in the urban patients than the rural patients. The lower BMI of 
the patients in the rural centre may be an indicator of malnutrition due to the prevailing 
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unfavorable socioeconomic state caused by a lower proportion of patients in formal 
employment.  
58.7% of those who died on commencement of HAART died within the first six months. This 
finding is supported by a number of papers written in different climes (46-48). Research has 
identified a number of factors that lead to early mortality after commencing HAART. These 
include late diagnosis of HIV infection in Sub-Saharan Africa (48), tuberculosis, acute sepsis, 
cryptococcal meningitis, wasting syndrome, malignancy and immune reconstitution syndrome 
(48-50). The concern of immune reconstitution syndrome (IRIS) as a major cause of early 
mortality following the initiation of HAART does not appear to be very important in Sub-
Saharan Africa, rather our problem is late diagnosis of HIV infection characterized by patients 
with low CD4 count at initiation harboring a number of AIDS defining conditions (49). A nested 
case-control study done with an urban African cohort to determine the incidence and elucidate 
the risk factors for IRIS found the cases of IRIS to be mild and not leading to mortality and put 
the incidence of IRIS at about 10% (51). Other risk factors for early mortality include male sex 
and oesophageal Candidiasis and the risk of mortality in the first six months could be as high as 
70% in some settings (52).  
Other predictors of mortality in these cohorts include BMI at initiation of therapy, WHO stage, 
baseline CD4 count, anaemia and age at HAART initiation. The presence of malnutrition at the 
onset of HAART reduces the chances of survival while on therapy (28, 53). The Cox models for 
both cohorts showed that higher BMI at initiation of HAART is associated with reduced hazards 
of mortality. Those with better nutritional status at initiation of treatment were also more likely 
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to achieve immunologic and virologic response at six months. This finding demonstrates the 
importance of optimizing patients’ nutritional status as an important component of pre-ARV 
care. The adverse effect of malnutrition on HIV treatment outcomes has been documented 
extensively (28, 54, 55). The older a patient is at the time of initiating HAART, the more likely 
the individual is to die, the less likely to achieve immunologic response and the more likely to 
achieve virologic response.  
The patients in both cohorts were equally likely to achieve immunologic and virologic response 
at 6 months of therapy. The finding of better immunologic response in those with lower CD4 
cell count at initiation of HAART merits further discussion here. It appears it is easier for 
patients with lower CD4 counts at baseline to have a 50 cell/µL increase than those with higher 
baseline CD4 counts, though they still have higher mortality rates as shown in the Cox hazards 
model. This may be due to the fact that they take a longer time to achieve a CD4 cell count of > 
200 cells/µL, hence still susceptible to opportunistic infections (37).  
Having discussed the findings above, it is important to state the limitations of the study since all 
interpretations of these findings must be done with these limitations in mind. 
4.2 LIMITATIONS OF THE STUDY 
It is possible that the centres chosen to represent the urban and rural areas of South Africa may 
not be representative of other centres. Therefore, the results of this study may not be 
generalizable. Different centres use different treatment protocols and may even differ by the 
predominant WHO stage at which the patients present. There may also be differences between 
government run and non-governmental sites.   
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About 21% of the patients were lost to follow up in the first six months of the study. The high 
proportion of individuals lost to follow up has a potential of creating bias in the study if those 
lost to follow up are systematically different from the rest of the cohort. A number of those 
classified as “lost to follow up” in the rural cohort may actually have died without being 
properly documented. This ‘loss to follow up’ level corresponds with what has been observed in 
many HIV treatment centres resource-poor settings (56, 57).  
The urban cohort mortality data used for this study, but not the rural cohort data had been 
updated with the South African national mortality database. This suggests the possibility of 
missing records of mortality among the rural cohort. This has made the direct comparison of 
mortality rates in the two cohorts liable to mortality-ascertaining bias. This necessitated 
comparing the predictors of mortality in both cohorts instead of a direct comparison of 
mortality rates in both cohorts. 
 This study, being a retrospective analysis of data, may have the problem of not collecting data 
on all the possible variables that may have an effect on mortality, immunologic and virologic 
response. It would be desirable to have information on the hepatitis B and C status of the 
patients and the presence or otherwise of chronic diseases like hypertension and diabetes 
mellitus that may have an impact on mortality. This introduces the likelihood of residual 
confounding into the study.  
Despite the limitations outlined above, this study has a number of strengths. The large sample 
size affords an opportunity to find a difference in outcomes if there really is one. There is a 
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paucity of studies comparing treatment outcomes in urban and rural Africa; therefore, this 
study will serve as a foundational study for such research.  
4.3 CONCLUSION 
HIV treatment outcomes – immunologic response and virologic response – do not differ 
between rural and urban South Africa. CD4 count, WHO stage at initiation of HAART and BMI 
are the factors that predict mortality in both cohorts. 
 
4.4 RECOMMENDATIONS 
Good nutritional support programs should be put in place in the pre-ARV clinics in both urban 
and rural areas to optimize patients’ nutritional status before commencement of HAART. This 
may help in reducing mortality, especially in the first six months of therapy. Majority of patients 
die within the first 6 months of commencement of HAART as shown in this study which 
correlates with late stage of HIV/AIDS. Continued public health enlightenment campaigns 
should be undertaken to ensure patients present early and benefit from treatment. This will not 
only enhance HAART but also significantly reduce the burden of disease in sub-Saharan Africa.  
Early diagnosis of HIV disease and early initiation of HAART at CD4 count of 350 cells/µL or 
lower instead of the 200 cells/ µL may also improve survival in HIV patients in Sub-Saharan 
Africa. 
The vital status of patients in the rural cohort should be updated with the South African 
national mortality database and this analysis repeated. 
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